Nanocrystals, compositions, and methods that aid particle transport in mucus
Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
1. A method, comprising:
delivering to a mucus membrane a composition comprising a plurality of coated particles, wherein the coated particle comprises:
a core particle comprising a solid pharmaceutical agent or a salt thereof, wherein the agent or salt has an aqueous solubility of less than or equal to 1 mg/mL at 25° C. at any point throughout the pH range,
wherein the pharmaceutical agent or salt thereof constitutes at least 95 wt % of the core particle; and
a coating comprising a surface-altering agent surrounding the core particle,
wherein the surface-altering agent comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least 2 kDa, and the hydrophilic blocks constitute at least 15 wt % of the triblock copolymer,
wherein the hydrophobic block associates with the surface of the core particle,
wherein the hydrophilic block is present at the surface of the coated particle and renders the coated particle hydrophilic, and
wherein the surface-altering agent is present on the surface of the core particle at a density of at least 0.001 molecules per nanometer squared; and
wherein the coated particles have a relative velocity of greater than 0.5 in mucus.
2. The method of claim 1 , wherein the surface-altering agent is covalently attached to the core particles.
3. The method of claim 1 , wherein the surface-altering agent is non-covalently adsorbed to the core particles.
4. The method of claim 1 , wherein the surface-altering agent is present on the surfaces of the coated particles at a density of at least 0.01 molecules per nanometer squared.
5. The method of claim 1 , wherein the hydrophilic blocks of the triblock copolymer constitute at least 30 wt % of the triblock copolymer.
6. The method of claim 1 , wherein the hydrophilic block of the triblock copolymer comprises poly(ethylene oxide) or poly(ethylene glycol) or a derivative thereof.
7. The method of claim 1 , wherein the hydrophobic block of the triblock copolymer is poly(propylene oxide).
8. The method of claim 1 , wherein the triblock copolymer is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) or poly(ethylene glycol)-poly(propylene oxide)-poly(ethylene glycol).
9. The method of claim 6 , wherein the poly(ethylene oxide) or poly(ethylene glycol) block has a molecular weight of at least 2 kDa.
10. The method of claim 7 , wherein the poly(propylene oxide) block has a molecular weight of at least 3 kDa.
11. The method of claim 1 , wherein each of the core particles comprises a crystalline pharmaceutical agent or a salt thereof.
12. The method of claim 1 , wherein each of the core particles comprises an amorphous pharmaceutical agent or a salt thereof.
13. The method of claim 1 , wherein each of the core particles comprises a salt of the solid pharmaceutical agent.
14. The method of claim 1 , wherein the pharmaceutical agent is at least one of a therapeutic agent or a diagnostic agent.
15. The method of claim 1 , wherein the pharmaceutical agent is at least one of a small molecule, a peptide, a peptidomimetic, a protein, a nucleic acid, or a lipid.
16. The method of claim 1 , wherein the pharmaceutical agent or a salt thereof has an aqueous solubility of less than or equal to 0.1 mg/mL at 25° C.
17. The method of claim 1 , wherein the coated particles have an average size of at least 20 nm and less than or equal to 1 μm.
18. The method of claim 1 , wherein the coated particles diffuse through human cervicovaginal mucus at a diffusivity that is greater than 1/500 the diffusivity that the particles diffuse through water on a time scale of 1 second.
19. The method of claim 1 , wherein the coated particles have a relative velocity of greater than 0.8 in mucus.
20. A method of forming coated particles, comprising:
combining core particles with a solution comprising a surface-altering agent,
wherein the core particles comprise a solid pharmaceutical agent or a salt thereof, wherein the agent or salt has a solubility of less than or equal to 1 mg/mL in the solution at 25° C.,
wherein the pharmaceutical agent or salt thereof constitutes at least 95 wt % of each of the core particles; and
coating the core particles with the surface-altering agent to form coated particles,
wherein the surface-altering agent comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least 2 kDa, and the hydrophilic blocks constitute at least 15 wt % of the triblock copolymer,
wherein the hydrophobic block associates with the surface of the core particles,
wherein the hydrophilic block is present at the surface of the coated particles and renders the coated particles hydrophilic, and
wherein the coated particles have a relative velocity of greater than 0.5 in mucus.